Purchase this article with an account.
S. Patil, S. Pilli, D. Mathapati, M. Chandran, G. Ansari, S. Mackenzie, J. Jarzabek, G. Menon; Role of Intravitreal Bevacizumab (Avastin) in the Management of Peripapillary Choroidal Neovascular Membrane. Invest. Ophthalmol. Vis. Sci. 2008;49(13):328.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess the effects of intravitreal bevacizumab as a primary treatment for peripapillary choroidal neovascularization (CNV) threatening the fovea.
Data for three consecutive patients with sight threatening peripapillary CNV that were treated with intravitreal bevacizumab (1.25mg) injection were reviewed retrospectively. Main outcome measures included best-corrected visual acuity (BCVA), central macular thickness (CMT) measured by optical coherence tomography (OCT) and complete resolution of CNV at 12,24 and 52 weeks.
Over a mean follow-up period of 10 months(range, 6-12 months), 2 eyes received 2 injections and 1 eye required 3 injections at 6-weekly intervals to ensure complete resolution of the CNV. The CNV resolved completely in all the affected eyes (100%). The BCVA improved in 1 eye from logmar 0.8 to 0.2 and remained stable in the other 2 eyes, log mar 1.0 pre and post treatment. The CMT(graph1) decreased significantly (p<0.001) after the treatment. No adverse events occured.
Intravitreal bevacizumab injection was found to be a safe and effective treatment option for peripapillary CNV in this case series with a one-year follow-up. It is difficult to conduct randomized clinical trials for this condition, but this case-series suggests the need for further case-series with larger sample size to assess the benefits of bevacizumab in this condition.
This PDF is available to Subscribers Only